Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 55, Issue 2, 2014, Pages 415-424

  Bu, Rong ^a   Hussain, Azhar R ^a   Al Obaisi, Khadija A S ^a   Ahmed, Maqbool ^a   Uddin, Shahab ^a   Al Kuraya, Khawla S ^a,b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b ALFAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

ABC; Apoptosis; NF B

Indexed keywords

BORTEZOMIB; I KAPPA B ALPHA; PROTEIN BCL 2; PROTEIN BCL 6; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

ACTIVATED B CELL TYPE LYMPHOMA; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL DEATH; CELL VIABILITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GEL MOBILITY SHIFT ASSAY; GENE CONTROL; GROWTH INHIBITION; LABORATORY; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; BCL-X PROTEIN; BORONIC ACIDS; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; I-KAPPA B PROTEINS; IMMUNOBLOTTING; INHIBITOR OF APOPTOSIS PROTEINS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MITOCHONDRIA; NF-KAPPA B; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; SIGNAL TRANSDUCTION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84904283182     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.806799     Document Type: Article

References (41)

1. Abramson JS, Shipp MA Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005;106:1164-1174. (Pubitemid 41129574)
2. AI-Eid H.S., Arteh S. Cancer incidence report: Saudi Arabia 2004. Kingdom of Saudi Arabia Ministry of Health, Saudi Cancer Registry, 2008. Available from: www.scr.org.sa
3. Alizadeh AA, Eisen MB, Davis R.E., et al Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511. (Pubitemid 30082188)
4. Rosenwald A, Wright G, Chan W.C., et al The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947. (Pubitemid 34651353)
5. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003, 198:851-862. (Pubitemid 37152922)
6. Savage KJ, Monti S, Kutok J.L., et al The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003, 102:3871-3879. (Pubitemid 37486965)
7. Lenz G, Wright G, Dave S.S., et al Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323.
8. Davis RE, Brown KD, Siebenlist U, et al Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-1874. (Pubitemid 34028664)
9. Lam LT, Davis RE, Pierce I, et al Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005, 11:28-40. (Pubitemid 40075775)
10. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 1986;47:921-928. (Pubitemid 17005065)
11. Nishikori M. Classical and alternative NF-kB activation pathways and their roles in lymphoid malignancies. J Clin Exp Hematopathol 2005;45:15-24.
12. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006;124:823-835. (Pubitemid 43261455)
13. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001; 107:241-246. (Pubitemid 32157954)
14. Mayo MW, Baldwin AS The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 2000; 1470:M55-M62. (Pubitemid 30155606)
15. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000. 18: 621-663. (Pubitemid 30365393)
16. Schmukle AC, Walczak H. No one can whistle a symphony alone - how different ubiquitin linkages cooperate to orchestrate NF-kappaB activity. J Cell Sci 2012;125:549-559.
17. Inobe T, Fishbain S, Prakash S., et al Defining the geometry of the two-component proteasome degron. Nat Chem Biol 2011;7: 161-167.
18. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994;79:13-21. (Pubitemid 24309509)
19. Scheidereit C. IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene 2006;25:6685-6705. (Pubitemid 44657846)
20. Kim HJ, Hawke N, Baldwin AS NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 2006;13:738-747.
21. Karin M. NF-kappaB and cancer: mechanisms and targets. Mol Carcinog 2006;45:355-361.
22. Naugler WE, Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 2008;18:19-26.
23. Uddin S, Hussain AR, Ahmed M, et al Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma. Haematologica 2012;97:1092-1100.
24. Uddin S, Hussain AR, Manogaran P.S., et al Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene 2005;24:7022-7030. (Pubitemid 41573631)
25. Hussain AR, Al-Jomah NA, Siraj A.K., et al Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells. Cancer Res 2007;67:3888-3897. (Pubitemid 46762177)
26. Hussain AR, Ahmed M, Al-Jomah NA, et al Curcumin suppresses constitutive activation ofnuclear factor-kappa Band requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther 2008;7:3318-3329.
27. Uddin S, Hussain AR, Siraj A.K., et al Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006;108:4178-4186. (Pubitemid 44913290)
28. Uddin S, Hussain A, Ai-Hussein K, et al Inhibition of phosphatidylinositol 3'-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochem Biophys Res Commun 2004;320:932-938. (Pubitemid 38887233)
29. Killian PH, Kronski E, Michalik K, et al. Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2. Carcinogenesis 2012;33:2507-2519.
30. Yang YI, Lee KT, Park H.J., et al Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFkappaB pathway. Carcinogenesis 2012;33:2488-2498.
31. McDade TP, Perugini RA, Vittimberga FJ Jr, et al Ubiquitin-proteasome inhibition enhances apoptosis of human pancreatic cancer cells. Surgery 1999;126:371-377. (Pubitemid 29382805)
32. Traenckner EB, Wilk S, Baeuerle PA A proteasome inhibitor preventsactivation of NF-kappaB and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 1994;13:5433-5441. (Pubitemid 24351822)
33. Bharti AC, Shishodia S, Reuben J.M., et al Nuclear factor-kappaB and STAT3 are constituti'vely active in CD 138 + cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004;103:3175-3184. (Pubitemid 38451696)
34. Bharti AC, Donato N, Singh S., et al Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003;101:1053-1062. (Pubitemid 36139379)
35. Mujtaba T, Dou QP Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med 2011; 12:471-480.
36. Richardson PG, Hideshima T, Anderson KC Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003;10:361-369. (Pubitemid 37296062)
37. Williamson MJ, Blank JL, Bruzzese F.I., et al Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. Mol Cancer Ther 2006;5:3052-3061. (Pubitemid 46092046)
38. Dasmahapatra G, Lembersky D, Rahmani M., et al Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biol Ther 2009;8:808-819.
39. Goy A, Younes A, McLaughlin P., et al Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-675. (Pubitemid 46224166)
40. Dunleavy K, Pittaluga S, Czuczman M.S., et al Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069-6076.
41. Ruan J, Martin P, Furman R.R., et al Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690-697.